Trial Profile
A Parallel-Group, Double-Blind, Long Term Safety and Efficacy Trial of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 Oct 2019
Price :
$35
*
At a glance
- Drugs Verubecestat (Primary)
- Indications Alzheimer's disease
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 16 May 2018 This trial has been changed to discontinued in Austria (End date: 2018-02-13) and completed in Belgium (End date: 2018-04-17).
- 05 May 2018 This trial has been changed to discontinued in Finland.
- 28 Apr 2018 This study has been completed in Finland.